Synergy CHC Corp. 8-K

What Happened
Synergy CHC Corp. (SNYR) reported on Form 8-K that on February 27, 2026 it was notified by Gravity Pharma General Trading LLC that Gravity is terminating, ab initio, the Brand License Agreement dated March 31, 2025 (amended June 30, 2025). The agreement granted Gravity an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey.

Key Details

• Termination notice received: February 27, 2026.
• Original Brand License Agreement date: March 31, 2025; amended by Amendment No. 1 on June 30, 2025.
• Territory covered: United Arab Emirates and Turkey.
• Aggregate license fee: $2.9 million — the company previously accounted for this fee as revenue.
• Synergy CHC says it continues to pursue registration and marketing of the licensed IP in the Territory.

Why It Matters
The filing highlights a contract termination that affects licensing rights in two international markets and involves a previously recognized $2.9M license fee. The 8-K notes the fee was recorded as revenue but does not disclose any reversal or financial adjustment in this filing. Investors should be aware this event could have implications for future revenues and international distribution plans; Synergy CHC is continuing efforts to register and market the products in the UAE and Turkey.